The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Recent evidence points to Myc--a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers--as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0022284&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727527611793408 |
|---|---|
| author | Mauro Savino Daniela Annibali Nicoletta Carucci Emilia Favuzzi Michael D Cole Gerard I Evan Laura Soucek Sergio Nasi |
| author_facet | Mauro Savino Daniela Annibali Nicoletta Carucci Emilia Favuzzi Michael D Cole Gerard I Evan Laura Soucek Sergio Nasi |
| author_sort | Mauro Savino |
| collection | DOAJ |
| description | Recent evidence points to Myc--a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers--as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of the Myc interfering molecule termed Omomyc, which demonstrated astounding therapeutic efficacy in transgenic mouse cancer models in vivo. Omomyc action is different from the one that can be obtained by gene knockout or RNA interference, approaches designed to block all functions of a gene product. This molecule--instead--appears to cause an edge-specific perturbation that destroys some protein interactions of the Myc node and keeps others intact, with the result of reshaping the Myc transcriptome. Omomyc selectively targets Myc protein interactions: it binds c- and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to promoters and transrepression. This is accompanied by broad epigenetic changes such as decreased acetylation and increased methylation at H3 lysine 9. In the presence of Omomyc, the Myc interactome is channeled to repression and its activity appears to switch from a pro-oncogenic to a tumor suppressive one. Given the extraordinary therapeutic impact of Omomyc in animal models, these data suggest that successfully targeting Myc for cancer therapy might require a similar twofold action, in order to prevent Myc/Max binding to E-boxes and, at the same time, keep repressing genes that would be repressed by Myc. |
| format | Article |
| id | doaj-art-87fb9854901348e2bd4e187527a28c7e |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-87fb9854901348e2bd4e187527a28c7e2025-08-20T03:09:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2228410.1371/journal.pone.0022284The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.Mauro SavinoDaniela AnnibaliNicoletta CarucciEmilia FavuzziMichael D ColeGerard I EvanLaura SoucekSergio NasiRecent evidence points to Myc--a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers--as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of the Myc interfering molecule termed Omomyc, which demonstrated astounding therapeutic efficacy in transgenic mouse cancer models in vivo. Omomyc action is different from the one that can be obtained by gene knockout or RNA interference, approaches designed to block all functions of a gene product. This molecule--instead--appears to cause an edge-specific perturbation that destroys some protein interactions of the Myc node and keeps others intact, with the result of reshaping the Myc transcriptome. Omomyc selectively targets Myc protein interactions: it binds c- and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to promoters and transrepression. This is accompanied by broad epigenetic changes such as decreased acetylation and increased methylation at H3 lysine 9. In the presence of Omomyc, the Myc interactome is channeled to repression and its activity appears to switch from a pro-oncogenic to a tumor suppressive one. Given the extraordinary therapeutic impact of Omomyc in animal models, these data suggest that successfully targeting Myc for cancer therapy might require a similar twofold action, in order to prevent Myc/Max binding to E-boxes and, at the same time, keep repressing genes that would be repressed by Myc.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0022284&type=printable |
| spellingShingle | Mauro Savino Daniela Annibali Nicoletta Carucci Emilia Favuzzi Michael D Cole Gerard I Evan Laura Soucek Sergio Nasi The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE |
| title | The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. |
| title_full | The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. |
| title_fullStr | The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. |
| title_full_unstemmed | The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. |
| title_short | The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. |
| title_sort | action mechanism of the myc inhibitor termed omomyc may give clues on how to target myc for cancer therapy |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0022284&type=printable |
| work_keys_str_mv | AT maurosavino theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT danielaannibali theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT nicolettacarucci theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT emiliafavuzzi theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT michaeldcole theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT gerardievan theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT laurasoucek theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT sergionasi theactionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT maurosavino actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT danielaannibali actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT nicolettacarucci actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT emiliafavuzzi actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT michaeldcole actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT gerardievan actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT laurasoucek actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy AT sergionasi actionmechanismofthemycinhibitortermedomomycmaygivecluesonhowtotargetmycforcancertherapy |